CymitQuimica logo

CAS 177575-17-6: N-[[5-[2-[(6S)-2-Amino-4,6,7,8-tetrahydro-4-oxo-3H-pyrimido[5,4-b][1,4]thiazin-6-yl]ethyl]-2-thienyl]carbonyl]-L-glutamic acid

Formula:C18H21N5O6S2
InChI:InChI=1S/C18H21N5O6S2/c19-18-22-14-13(16(27)23-18)31-9(7-20-14)2-1-8-3-5-11(30-8)15(26)21-10(17(28)29)4-6-12(24)25/h3,5,9-10H,1-2,4,6-7H2,(H,21,26)(H,24,25)(H,28,29)(H4,19,20,22,23,27)/t9-,10-/m0/s1
InChI key:InChIKey=HHKAOUMVRGSKLS-UWVGGRQHSA-N
SMILES:O=C1C2=C(NC[C@H](CCC=3SC(C(N[C@@H](CCC(O)=O)C(O)=O)=O)=CC3)S2)NC(N)=N1
Synonyms:
  • <span class="text-smallcaps">L</span>-Glutamic acid, N-[[5-[2-(2-amino-4,6,7,8-tetrahydro-4-oxo-1H-pyrimido[5,4-b][1,4]thiazin-6-yl)ethyl]-2-thienyl]carbonyl]-, (S)-
  • <span class="text-smallcaps">L</span>-Glutamic acid, N-[[5-[2-[(6S)-2-amino-4,6,7,8-tetrahydro-4-oxo-1H-pyrimido[5,4-b][1,4]thiazin-6-yl]ethyl]-2-thienyl]carbonyl]-
  • <span class="text-smallcaps">L</span>-Glutamic acid, N-[[5-[2-[(6S)-2-amino-4,6,7,8-tetrahydro-4-oxo-3H-pyrimido[5,4-b][1,4]thiazin-6-yl]ethyl]-2-thienyl]carbonyl]-
  • AG-2033((6R)-isomer)
  • Ag-2034
  • N-[(5-{2-[(6S)-2-amino-4-oxo-4,6,7,8-tetrahydro-1H-pyrimido[5,4-b][1,4]thiazin-6-yl]ethyl}thiophen-2-yl)carbonyl]-L-glutamic acid
  • N-[[5-[2-[(6S)-2-Amino-4,6,7,8-tetrahydro-4-oxo-3H-pyrimido[5,4-b][1,4]thiazin-6-yl]ethyl]-2-thienyl]carbonyl]-<span class="text-smallcaps">L</span>-glutamic acid
  • N-[[5-[2-[(6S)-2-Amino-4,6,7,8-tetrahydro-4-oxo-3H-pyrimido[5,4-b][1,4]thiazin-6-yl]ethyl]-2-thienyl]carbonyl]-L-glutamic acid
  • L-Glutamic acid, N-[[5-[2-(2-amino-4,6,7,8-tetrahydro-4-oxo-1H-pyrimido[5,4-b][1,4]thiazin-6-yl)ethyl]-2-thienyl]carbonyl]-, (S)-
  • L-Glutamic acid, N-[[5-[2-[(6S)-2-amino-4,6,7,8-tetrahydro-4-oxo-1H-pyrimido[5,4-b][1,4]thiazin-6-yl]ethyl]-2-thienyl]carbonyl]-
  • L-Glutamic acid, N-[[5-[2-[(6S)-2-amino-4,6,7,8-tetrahydro-4-oxo-3H-pyrimido[5,4-b][1,4]thiazin-6-yl]ethyl]-2-thienyl]carbonyl]-
Sort by

Found 2 products.
  • AG2034

    CAS:
    AG2034 is a drug that is currently in development for the treatment of autoimmune diseases and prostate cancer. AG2034 has been shown to selectively inhibit the MAPK signal pathway at physiological levels, but not ATP levels. This drug also inhibits the cycle of DNA replication and transcription by binding to DNA gyrase, a type of enzyme that maintains the integrity of bacterial DNA. The drug has been shown to have no antimicrobial activity against bacteria, which may be due to its lack of antibiotic properties. AG2034 was synthesized using an asymmetric synthesis reaction with cell cultures and tissue culture techniques.
    Formula:C18H21N5O6S2
    Purity:Min. 95%
    Molecular weight:467.52 g/mol

    Ref: 3D-FA46643

    ne
    To inquire
  • AG2034

    CAS:
    AG2034 is an inhibitor of the glycinamide ribonucleotide formyltransferase (GARFT).
    Formula:C18H21N5O6S2
    Color and Shape:Solid
    Molecular weight:467.52

    Ref: TM-T26572

    25mg
    3,155.00€
    50mg
    4,161.00€
    100mg
    5,795.00€